

# **Human Recombinant Insulin Market By Application (Type I Diabetes, Type II Diabetes) , By Product Type (Long-acting, Short-acting, Premixed, Intermediate-acting) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033**

<https://marketpublishers.com/r/H98ABCACDBF2EN.html>

Date: August 2024

Pages: 300

Price: US\$ 2,655.00 (Single User License)

ID: H98ABCACDBF2EN

## **Abstracts**

Human Recombinant Insulin Market Expected to Garner \$34.7 Billion by 2033, Growing at a CAGR of 2.4%

Abstract: The global human recombinant insulin market is expected to grow primarily due to the rising global incidence of type 1 and type 2 diabetes which is significantly boosting the demand for insulin therapies. The North America region is predicted to witness profitable growth by 2033.

As per the report published by Research Dive, the global human recombinant insulin market was valued at \$27.6 billion in 2023 and is expected to register a revenue of \$34.7 billion by 2033 at a CAGR of 2.4% during the forecast period 2024-2033.

### **Dynamics of the Market**

The global increase in type 1 and type 2 diabetes cases and the increasing government support for development of advanced healthcare facilities are expected to make the human recombinant insulin market a highly profitable one in the forecast period. Besides, the recombinant human insulin's effectiveness in managing diabetes and its compatibility with patients' needs highlight its critical role in diabetes treatment.

However, according to market analysts, the high cost of human recombinant insulin and the limited healthcare resources in certain regions might restrain the growth of the market.

Advancements in biotechnology and global market expansion are predicted to offer numerous growth opportunities for the market in the forecast period. Moreover, innovations in insulin production processes are leading to enhanced accessibility and affordability of recombinant human insulin, which is expected to propel the human recombinant insulin market forward in the coming years.

### Key Players of the Market

The major players of the human recombinant insulin market include Novo Nordisk A/S, Biocon Limited, Sanofi S.A., Bioton S.A., Eli Lilly and Company, Wanbang Biopharmaceuticals Co., Ltd., Zhuhai United Laboratories Co., Ltd., Dongbao Enterprise Group Co., Ltd, Julphar Gulf Pharmaceutical Industries, Medtronic plc., and Gan & Lee Pharmaceuticals, Ltd.

### What the Report Covers

In addition to the details highlighted in this description, the comprehensive final report delves into essential market aspects. These encompass a market overview, SWOT analysis, market dynamics, Porter's five forces analysis, segmentation (key trends, regional analysis, and forecast analysis), and company profiles (including company overview, product portfolio, operating segments, strategic initiatives, and financial performance).

Additional benefits you will get with this purchase are:

Quarterly Update and\* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to

16 analyst hours to solve questions, and post-sale queries)

15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response\*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Investment Opportunities

Product Benchmarking / Product specification and applications

Technology Trend Analysis

Market share analysis of players by products/segments

New Product Development/ Product Matrix of Key Players

Regulatory Guidelines

Additional company profiles with specific to client's interest

Additional country or region analysis- market size and forecast

Criss-cross segment analysis- market size and forecast

Expanded list for Company Profiles

Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Market share analysis of players at global/region/country level

SWOT Analysis

## Key Market Segments

### By Application

Type I Diabetes

Type II Diabetes

### By Product Type

Long-acting

Short-acting

Premixed

Intermediate-acting

### By Distribution Channel

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

### By Region

North America

U.S.

Canada

Mexico

Europe

France

Germany

Italy

Spain

UK

Rest of Europe

Asia-Pacific

China

Japan

India

South Korea

Australia

Rest of Asia-Pacific

LAMEA

Brazil

South Africa

Saudi Arabia

UAE

Rest of LAMEA

Key Market Players

Novo Nordisk A/S

Sanofi S.A.

Biocon Limited

Bioton S.A.

Wanbang Biopharmaceuticals Co., Ltd.

Eli Lilly and Company

Zhuhai United Laboratories Co. Ltd.

Julphar Gulf Pharmaceutical Industries

Dongbao Enterprise Group Co., Ltd.

Medtronic plc.

## Contents

### CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models

### CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

### CHAPTER 3: MARKET LANDSCAPE

- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
  - 3.4.1. Drivers
  - 3.4.2. Restraints
  - 3.4.3. Opportunities

### CHAPTER 4: HUMAN RECOMBINANT INSULIN MARKET, BY APPLICATION

- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Application
- 4.2. Type I Diabetes
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities

- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Type II Diabetes
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country

## **CHAPTER 5: HUMAN RECOMBINANT INSULIN MARKET, BY PRODUCT TYPE**

- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Product Type
- 5.2. Long-acting
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Short-acting
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
- 5.4. Premixed
  - 5.4.1. Key Market Trends, Growth Factors and Opportunities
  - 5.4.2. Market Size and Forecast, By Region
  - 5.4.3. Market Share Analysis, By Country
- 5.5. Intermediate-acting
  - 5.5.1. Key Market Trends, Growth Factors and Opportunities
  - 5.5.2. Market Size and Forecast, By Region
  - 5.5.3. Market Share Analysis, By Country

## **CHAPTER 6: HUMAN RECOMBINANT INSULIN MARKET, BY DISTRIBUTION CHANNEL**

- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Online Pharmacies
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities

- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Retail Pharmacies
  - 6.4.1. Key Market Trends, Growth Factors and Opportunities
  - 6.4.2. Market Size and Forecast, By Region
  - 6.4.3. Market Share Analysis, By Country

## **CHAPTER 7: HUMAN RECOMBINANT INSULIN MARKET, BY REGION**

- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
  - 7.2.1. Key Market Trends and Opportunities
  - 7.2.2. Market Size and Forecast, By Application
  - 7.2.3. Market Size and Forecast, By Product Type
  - 7.2.4. Market Size and Forecast, By Distribution Channel
  - 7.2.5. Market Size and Forecast, By Country
  - 7.2.6. U.S. Human Recombinant Insulin Market
    - 7.2.6.1. Market Size and Forecast, By Application
    - 7.2.6.2. Market Size and Forecast, By Product Type
    - 7.2.6.3. Market Size and Forecast, By Distribution Channel
  - 7.2.7. Canada Human Recombinant Insulin Market
    - 7.2.7.1. Market Size and Forecast, By Application
    - 7.2.7.2. Market Size and Forecast, By Product Type
    - 7.2.7.3. Market Size and Forecast, By Distribution Channel
  - 7.2.8. Mexico Human Recombinant Insulin Market
    - 7.2.8.1. Market Size and Forecast, By Application
    - 7.2.8.2. Market Size and Forecast, By Product Type
    - 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
  - 7.3.1. Key Market Trends and Opportunities
  - 7.3.2. Market Size and Forecast, By Application
  - 7.3.3. Market Size and Forecast, By Product Type
  - 7.3.4. Market Size and Forecast, By Distribution Channel
  - 7.3.5. Market Size and Forecast, By Country
  - 7.3.6. France Human Recombinant Insulin Market
    - 7.3.6.1. Market Size and Forecast, By Application
    - 7.3.6.2. Market Size and Forecast, By Product Type
    - 7.3.6.3. Market Size and Forecast, By Distribution Channel

- 7.3.7. Germany Human Recombinant Insulin Market
  - 7.3.7.1. Market Size and Forecast, By Application
  - 7.3.7.2. Market Size and Forecast, By Product Type
  - 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Human Recombinant Insulin Market
  - 7.3.8.1. Market Size and Forecast, By Application
  - 7.3.8.2. Market Size and Forecast, By Product Type
  - 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Human Recombinant Insulin Market
  - 7.3.9.1. Market Size and Forecast, By Application
  - 7.3.9.2. Market Size and Forecast, By Product Type
  - 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Human Recombinant Insulin Market
  - 7.3.10.1. Market Size and Forecast, By Application
  - 7.3.10.2. Market Size and Forecast, By Product Type
  - 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Human Recombinant Insulin Market
  - 7.3.11.1. Market Size and Forecast, By Application
  - 7.3.11.2. Market Size and Forecast, By Product Type
  - 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
  - 7.4.1. Key Market Trends and Opportunities
  - 7.4.2. Market Size and Forecast, By Application
  - 7.4.3. Market Size and Forecast, By Product Type
  - 7.4.4. Market Size and Forecast, By Distribution Channel
  - 7.4.5. Market Size and Forecast, By Country
  - 7.4.6. China Human Recombinant Insulin Market
    - 7.4.6.1. Market Size and Forecast, By Application
    - 7.4.6.2. Market Size and Forecast, By Product Type
    - 7.4.6.3. Market Size and Forecast, By Distribution Channel
  - 7.4.7. Japan Human Recombinant Insulin Market
    - 7.4.7.1. Market Size and Forecast, By Application
    - 7.4.7.2. Market Size and Forecast, By Product Type
    - 7.4.7.3. Market Size and Forecast, By Distribution Channel
  - 7.4.8. India Human Recombinant Insulin Market
    - 7.4.8.1. Market Size and Forecast, By Application
    - 7.4.8.2. Market Size and Forecast, By Product Type
    - 7.4.8.3. Market Size and Forecast, By Distribution Channel
  - 7.4.9. South Korea Human Recombinant Insulin Market

- 7.4.9.1. Market Size and Forecast, By Application
- 7.4.9.2. Market Size and Forecast, By Product Type
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Human Recombinant Insulin Market
  - 7.4.10.1. Market Size and Forecast, By Application
  - 7.4.10.2. Market Size and Forecast, By Product Type
  - 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Human Recombinant Insulin Market
  - 7.4.11.1. Market Size and Forecast, By Application
  - 7.4.11.2. Market Size and Forecast, By Product Type
  - 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
  - 7.5.1. Key Market Trends and Opportunities
  - 7.5.2. Market Size and Forecast, By Application
  - 7.5.3. Market Size and Forecast, By Product Type
  - 7.5.4. Market Size and Forecast, By Distribution Channel
  - 7.5.5. Market Size and Forecast, By Country
  - 7.5.6. Brazil Human Recombinant Insulin Market
    - 7.5.6.1. Market Size and Forecast, By Application
    - 7.5.6.2. Market Size and Forecast, By Product Type
    - 7.5.6.3. Market Size and Forecast, By Distribution Channel
  - 7.5.7. South Africa Human Recombinant Insulin Market
    - 7.5.7.1. Market Size and Forecast, By Application
    - 7.5.7.2. Market Size and Forecast, By Product Type
    - 7.5.7.3. Market Size and Forecast, By Distribution Channel
  - 7.5.8. Saudi Arabia Human Recombinant Insulin Market
    - 7.5.8.1. Market Size and Forecast, By Application
    - 7.5.8.2. Market Size and Forecast, By Product Type
    - 7.5.8.3. Market Size and Forecast, By Distribution Channel
  - 7.5.9. UAE Human Recombinant Insulin Market
    - 7.5.9.1. Market Size and Forecast, By Application
    - 7.5.9.2. Market Size and Forecast, By Product Type
    - 7.5.9.3. Market Size and Forecast, By Distribution Channel
  - 7.5.10. Rest of LAMEA Human Recombinant Insulin Market
    - 7.5.10.1. Market Size and Forecast, By Application
    - 7.5.10.2. Market Size and Forecast, By Product Type
    - 7.5.10.3. Market Size and Forecast, By Distribution Channel

## **CHAPTER 8: COMPETITIVE LANDSCAPE**

- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023

## **CHAPTER 9: COMPANY PROFILES**

- 9.1. Novo Nordisk A/S
  - 9.1.1. Company Overview
  - 9.1.2. Key Executives
  - 9.1.3. Company Snapshot
  - 9.1.4. Operating Business Segments
  - 9.1.5. Product Portfolio
  - 9.1.6. Business Performance
  - 9.1.7. Key Strategic Moves and Developments
- 9.2. Sanofi S.A.
  - 9.2.1. Company Overview
  - 9.2.2. Key Executives
  - 9.2.3. Company Snapshot
  - 9.2.4. Operating Business Segments
  - 9.2.5. Product Portfolio
  - 9.2.6. Business Performance
  - 9.2.7. Key Strategic Moves and Developments
- 9.3. Biocon Limited
  - 9.3.1. Company Overview
  - 9.3.2. Key Executives
  - 9.3.3. Company Snapshot
  - 9.3.4. Operating Business Segments
  - 9.3.5. Product Portfolio
  - 9.3.6. Business Performance
  - 9.3.7. Key Strategic Moves and Developments
- 9.4. Bioton S.A.
  - 9.4.1. Company Overview
  - 9.4.2. Key Executives
  - 9.4.3. Company Snapshot
  - 9.4.4. Operating Business Segments

- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Wanbang Biopharmaceuticals Co., Ltd.
  - 9.5.1. Company Overview
  - 9.5.2. Key Executives
  - 9.5.3. Company Snapshot
  - 9.5.4. Operating Business Segments
  - 9.5.5. Product Portfolio
  - 9.5.6. Business Performance
  - 9.5.7. Key Strategic Moves and Developments
- 9.6. Eli Lilly And Company
  - 9.6.1. Company Overview
  - 9.6.2. Key Executives
  - 9.6.3. Company Snapshot
  - 9.6.4. Operating Business Segments
  - 9.6.5. Product Portfolio
  - 9.6.6. Business Performance
  - 9.6.7. Key Strategic Moves and Developments
- 9.7. Zhuhai United Laboratories Co. Ltd.
  - 9.7.1. Company Overview
  - 9.7.2. Key Executives
  - 9.7.3. Company Snapshot
  - 9.7.4. Operating Business Segments
  - 9.7.5. Product Portfolio
  - 9.7.6. Business Performance
  - 9.7.7. Key Strategic Moves and Developments
- 9.8. Julphar Gulf Pharmaceutical Industries
  - 9.8.1. Company Overview
  - 9.8.2. Key Executives
  - 9.8.3. Company Snapshot
  - 9.8.4. Operating Business Segments
  - 9.8.5. Product Portfolio
  - 9.8.6. Business Performance
  - 9.8.7. Key Strategic Moves and Developments
- 9.9. Dongbao Enterprise Group Co., Ltd.
  - 9.9.1. Company Overview
  - 9.9.2. Key Executives
  - 9.9.3. Company Snapshot

- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Medtronic Plc.
  - 9.10.1. Company Overview
  - 9.10.2. Key Executives
  - 9.10.3. Company Snapshot
  - 9.10.4. Operating Business Segments
  - 9.10.5. Product Portfolio
  - 9.10.6. Business Performance
  - 9.10.7. Key Strategic Moves and Developments

## I would like to order

Product name: Human Recombinant Insulin Market By Application (Type I Diabetes, Type II Diabetes) ,  
By Product Type (Long-acting, Short-acting, Premixed, Intermediate-acting) By  
Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) :  
Global Opportunity Analysis and Industry Forecast, 2024-2033

Product link: <https://marketpublishers.com/r/H98ABCACDBF2EN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer  
Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click  
button on product page <https://marketpublishers.com/r/H98ABCACDBF2EN.html>